Vasopressin in chronic kidney disease: an elephant in the room?
about
A review of the nonpressor and nonantidiuretic actions of the hormone vasopressinExperimental therapies and ongoing clinical trials to slow down progression of ADPKDEarly diabetic nephropathy in type 1 diabetes: new insightsTolvaptan in autosomal dominant polycystic kidney disease: three years' experience.Increased insensible water loss contributes to aging related dehydration.Diabetes Complications in Childhood Diabetes-New Biomarkers and Technologies.Association between fluid intake and kidney function, and survival outcomes analysis: a nationwide population-based studyThe chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trialPotential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease.The Chronic Kidney Disease Water Intake Trial: Protocol of a Randomized Controlled TrialAcute and chronic effects of hydration status on health.Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 TrialEffect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.Plasma copeptin, a possible prognostic marker in cirrhosis.Hydration and kidney health.The impact of daily temperature on renal disease incidence: an ecological study.Validation of Surrogates of Urine Osmolality in Population Studies.Urinary extracellular vesicles as reservoirs of altered proteins during the pathogenesis of polycystic kidney disease.
P2860
Q21131156-57A0203D-E41C-4F2E-8AC8-88F81D40D115Q27001230-E22E8BE6-34DB-48D2-817E-4B95001175E9Q27021632-B4B1B799-8E86-4AAF-835F-D96B9BE636A2Q30424687-A477F038-E826-4E69-85BD-D65F16C8722BQ31017365-C8538D3A-22FE-4CB6-84CE-F2C4D2C7B37AQ36095944-65CDA68C-0CBD-4F68-90E2-3DAEF15CE5B2Q36920040-82EB1946-1599-4CD8-9C84-55ED1729F8CBQ37448445-6991C27D-5A22-4B1E-9173-F0755699D9C7Q37892306-4F51FD13-7FE1-4D5E-BCF7-9027EAD9C4E0Q38371440-F6F4897D-4F9A-4F3D-98AE-B66290BCC42AQ38569959-73D82381-0F9D-41D8-8AF0-F0B5B49000B5Q41076909-2AE75B08-5E7A-4E0A-BEC9-79BCCA182A6CQ41431126-858531C4-C777-4EE8-A01C-E9CDEBA87A7EQ43639386-831A638D-8F6D-433C-87E1-276DC3C7ED25Q45233930-30066746-B816-4FDC-85B3-4DF876078302Q47098909-E9FF8B94-6672-46A3-99E3-453DBF26C094Q48015191-22E4FA58-87D6-4888-BB85-8372E1FC667EQ52960506-ED59A0B9-74EB-4D77-AEA4-6E95CBE27FA5
P2860
Vasopressin in chronic kidney disease: an elephant in the room?
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Vasopressin in chronic kidney disease: an elephant in the room?
@en
type
label
Vasopressin in chronic kidney disease: an elephant in the room?
@en
prefLabel
Vasopressin in chronic kidney disease: an elephant in the room?
@en
P2860
P356
P1433
P1476
Vasopressin in chronic kidney disease: an elephant in the room?
@en
P2093
Vicente E Torres
P2860
P2888
P304
P356
10.1038/KI.2009.325
P407
P577
2009-11-01T00:00:00Z
P5875
P6179
1034731298